Atossa Genetics to Exhibit at American Congress of Obstetrics and Gynecology Meeting
ForeCYTE Breast Health Test for Detection of Precancer and Cancer to Be Displayed
(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 04/29/13 -- (NASDAQ: ATOS), The Breast Health Company™, will display its at the in New Orleans from May 4 - 8, 2013. The Atossa exhibit will be located in at the Ernest N. Morial Convention Center.
The ForeCYTE Breast Health Test, developed and marketed by , detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses a that is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about the ForeCYTE Test, click here:
"As ForeCYTE testing can provide vital early detection of cancer or precancerous conditions and save lives by doing so, we look forward to personally presenting its value to the largest gathering of gynecologists, obstetricians, and related professionals in the nation," noted Chris Destro, Vice President of Atossa, who will attend the exhibition.
Mr. Destro added, "Our recent contracts with and covering 97 million lives will help ensure access to our test within OB/GYN practices nationwide and ultimately help gain broader patient access."
Atossa's ForeCYTE Breast Health Test is available through physicians nationwide.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.
In addition to the ForeCYTE Breast Health Test, Atossa markets the , a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.
For additional information, please visit .
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics, Inc.
Chris Destro
Vice President
(O) 800-351-3902
(M) (206) 310-2335
Matthew D. Haines (Investors)
Managing Director
MBS Value Partners
212-710-9686
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.04.2013 - 06:30 Uhr
Sprache: Deutsch
News-ID 1221125
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SEATTLE, WA
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 161 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Atossa Genetics to Exhibit at American Congress of Obstetrics and Gynecology Meeting
"
steht unter der journalistisch-redaktionellen Verantwortung von
Atossa Genetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
